Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company headquartered in Tokyo, Japan, formed by the merger of Daiichi Pharmaceutical and Sankyo in 2005. It is a leading research-based organization with a significant presence in both the Japanese domestic market and international markets, including the United States and Europe. The company's core focus is on the research, development, and commercialization of innovative medicines, particularly in the therapeutic areas of oncology, cardiovascular disease, and rare diseases. Its portfolio includes both proprietary in-house discoveries and products developed through strategic alliances with firms like AstraZeneca and Merck & Co..

History

The company's origins trace back to its two predecessor firms, with Sankyo founded in 1899 and Daiichi Pharmaceutical established in 1915. The landmark merger in 2005 created one of Japan's largest pharmaceutical entities, aiming to enhance global competitiveness. A pivotal moment in its history was the 2008 acquisition of a majority stake in the Indian generic drug manufacturer Ranbaxy Laboratories, a move intended to expand its global footprint. However, significant challenges with Ranbaxy's regulatory compliance led to its eventual sale to Sun Pharmaceutical in 2014. The company later strengthened its oncology pipeline through the 2019 acquisition of Puma Biotechnology's Japanese subsidiary and entered a major collaboration with AstraZeneca for the development of datopotamab deruxtecan.

Business and operations

The company operates through two primary business segments: its innovative pharmaceutical business and its generic drugs business in Japan. Its global research and development network includes major facilities in Tokyo, Edison, and Münchenbuchsee in Switzerland. In the United States, its subsidiary Daiichi Sankyo, Inc. manages commercial operations, while in Europe, it maintains a significant presence through Daiichi Sankyo Europe GmbH, based in Munich. The company's manufacturing footprint spans multiple countries, with key production sites in Japan, Germany, and the United Kingdom, ensuring a robust supply chain for its global markets.

Products and research

The company's research strategy is heavily focused on antibody-drug conjugate (ADC) technology, a cornerstone of its oncology portfolio. Its flagship ADC, Enhertu (fam-trastuzumab deruxtecan-nxki), developed in partnership with AstraZeneca, is approved for treating HER2-positive breast cancer, gastric cancer, and non-small cell lung cancer. Another key ADC in its pipeline is datopotamab deruxtecan, being studied for lung cancer and breast cancer. Beyond oncology, its cardiovascular portfolio includes prominent antihypertensive agents such as Olmetec (olmesartan) and Benicar, and the anticoagulant Lixiana (edoxaban). The company also actively pursues research in rare diseases and vaccines.

Corporate affairs

The company is listed on the Tokyo Stock Exchange and is a constituent of the Nikkei 225 stock index. Its corporate governance structure includes a Board of Directors chaired by Sunao Manabe, who also serves as President and Chief Executive Officer. The firm maintains a comprehensive corporate social responsibility (CSR) program, focusing on access to medicines in developing countries, environmental sustainability, and support for disaster relief efforts, such as those following the 2011 Tōhoku earthquake and tsunami. It is also a member of various industry associations, including the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

Controversies and legal issues

The company has faced significant legal and regulatory challenges, primarily stemming from its association with Ranbaxy Laboratories. Following the acquisition, Ranbaxy faced allegations of data falsification and manufacturing violations from the U.S. Food and Drug Administration (FDA), leading to a historic $500 million settlement with the U.S. Department of Justice in 2013. Separately, the company was involved in litigation concerning the side effects of its antihypertensive drug Benicar, resulting in a multimillion-dollar settlement in 2017. More recently, it has been engaged in patent disputes related to its ADC technology with companies like Seagen, now part of Pfizer.

Category:Pharmaceutical companies of Japan Category:Companies listed on the Tokyo Stock Exchange Category:Companies based in Tokyo